WaferGen Biosystems this week appointed Sharat Singh as senior vice president of research and development and Christopher Maki as vice president of worldwide sales.
Singh is establishing and directing a core technology team charged with the development and commercialization of the company's SmartChip product. In this role, he will work closely with David Gelfand, WaferGen's chief scientific officer.
In addition, Singh, who will report directly to Alnoor Shivji, WaferGen's chairman and chief executive officer, will oversee the ongoing development of WaferGen's currently marketed SmartSlide platform.
Prior to joining WaferGen, Singh served as chief scientific officer at Aclara Biosciences.
Maki will be responsible for marketing WaferGen's SmartSlide product to target customers in the areas of live cell imaging and stem cell research. At the same time, he will be charged with developing and implementing a long-term global sales strategy for the introduction of the SmartChip product.
Maki joins WaferGen following more than six years at Molecular Devices (now part of MDS). At Molecular Devices, Maki most recently served as director of sales, research imaging, and high content screening.
Prior to his work with Molecular Devices, Maki served as northeast regional sales manager of Universal Imaging. He has also held various research positions at the Vollum Institute for Advanced Biomedical Research and the University of Pennsylvania.
Assay Designs this week announced that Michael Mullenix has joined the company as vice president for research and development.
Prior to joining Assay Designs, Mullenix was a principal scientist in Amgen’s clinical immunology group. Prior to joining Amgen, Mullenix held a series of R&D leadership positions with Molecular Staging, Becton Dickinson, and Strategic Diagnostics.
Assay Designs also announced this week that Gabriella Szekely-Klepser has joined the company as vice president of science and technology. Szekely-Klepser was previously an associate research fellow at Pfizer Global R&D, where she most recently was leader of the translational research biomarker implementation and biologics bioanalytical groups. Prior to her six years at Pfizer, Szekely-Klepser held various R&D positions at 3M.
Pfizer this week named Martin Mackay as president of Pfizer Global Research and Development; Corey Goodman as director if its new independent, stand-alone biotherapeutics and bioinnovation center; and Briggs Morrison, who held senior research and development positions at Merck, as senior vice president of clinical developmentfor the PGRD pipeline. (see also News Scan, this issue)
Mackay and Goodman will report to Pfizer CEO Jeff Kindler and become members of the company’s executive leadership team.